Lumino

What Lumino does

Lumino (Hello Lumino Limited) is a UK-based digital health company founded in 2020 that develops clinical-grade digital therapeutics combining Cognitive Behavioural Therapy (CBT) with digital delivery. Its first commercial product, Seren, is a menopause-specific CBT programme targeting symptoms such as hot flushes, anxiety, night sweats, and sleep issues, and is accessible directly via seren.health. The company's digital therapeutics are built to ISO 13485 medical device standards and Digital Therapeutics Assessment Criteria (DTAC) compliance for NHS England, positioning them as prescribable medical devices rather than consumer wellness applications, and they hold Cyber Essentials certification.

Lumino operates a B2B2C and direct-to-consumer go-to-market. The primary customer segments are UK healthcare systems (NHS trusts and health boards), employers offering workplace wellness programmes, and individual consumers seeking accessible therapy without waiting times or travel. Distribution leverages institutional partnerships with NHS Scotland, NHS Ayrshire and Arran, NHS Greater Glasgow and Clyde, NHS Golden Jubilee, CivTech, Health Innovation East, and the Chief Scientist Office, with revenue models described as recurring subscriptions via clinical prescription and employer contracts. The company operates from a registered headquarters in Bristol (17-18 Berkeley Square) and a Scotland office in Glasgow (26 Civic Street).

Lumino is privately held and backed by a mix of public-sector grants and corporate partners, including the Scottish Government, NHS Scotland, SBRI Wales, Bayer, NIHR, and Innovate UK, with a disclosed Innovate UK award of approximately $132,608 dated November 2020. The company is co-founded by Becky Cotton (CEO, former Director of Mental Health Policy at NHS Confederation, Cambridge Executive MBA, Innovate UK 2023 Women In Innovation awardee) and Mo Morgan (CSO, 20-year brand and digital product strategist). The company is actively recruiting and is open to additional private investors.

Name

Lumino

Legal name

Hello Lumino Limited

Website

https://hellolumino.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Lumino develops clinical-grade digital therapeutics combining Cognitive Behavioural Therapy with digital delivery, targeting UK NHS health systems, employers, and individual consumers. Its first product, Seren, is a menopause-specific CBT programme for symptoms such as hot flushes, anxiety, and sleep issues.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)

akta.pro primary industry

Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

akta.pro secondary industry

Condition-specific Digital Therapeutics (DTx) (HLACANAA)

Keywords

• Digital therapeutics
• Cognitive behavioral therapy
• Menopause treatment
• Mental health platform
• Medical device software

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Prescription/Clinical Access: Digital therapeutics prescribed through healthcare systems, potentially generating revenue through NHS commissioning or reimbursement pathways
2. Employer Wellness Programmes: B2B sales of condition-specific digital therapeutics to employers for workplace wellness offerings

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Lumino (Hello Lumino Limited) develops and delivers clinical-grade digital therapeutics designed to make mental health and menopause treatment more affordable and accessible. Its core product, Seren, is a menopause-specific Cognitive Behavioural Therapy (CBT) programme that addresses symptoms such as hot flushes, anxiety, night sweats, and sleep issues, and is built to ISO 13485 medical device standards with DTAC compliance so it can be prescribed alone or alongside other treatments via NHS systems and employer wellness programmes.

Product overview

Lumino offers a portfolio of digital therapeutics focused on clinical-grade mental health interventions. The company has launched Seren, its first core product, which is a menopause-specific CBT programme. Lumino's digital therapeutics are designed to be prescribed alone or alongside other treatments, combining clinical outcomes with engaging user experiences. The company positions itself as creating condition-specific treatments that address symptoms early to optimise scarce healthcare resources.

Differentiator

Problem solved

Functional benefit

Brands

• Seren: Seren is Lumino's first digital therapeutic - a menopause-specific Cognitive Behavioural Therapy (CBT) programme designed to help with symptoms such as hot flushes, anxiety, night sweats, and sleep issues that can persist for seven years or more.

Products and services

• Seren Menopause-specific Cognitive Behavioural Therapy (CBT) digital therapeutic programme designed to help women manage symptoms such as hot flushes, anxiety, night sweats, and sleep issues; available direct-to-consumer via seren.health and for clinical prescription via NHS systems and employer wellness programmes.

Quantifiable outcome

• CBT has been shown to help with significant menopause symptoms (anxiety, hot flushes, night sweats, sleep issues)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• CivTechcoreStrategic or Co-development PartnerPublic sector innovation programme that sponsors clinical advisors including Dr. Jen Sassarini and Dr. Kat Bjornsson, helping solve real-world NHS challenges.
• Chief Scientist OfficecoreStrategic or Co-development PartnerScotland's health research funding body supporting Lumino's evidence-based digital therapeutics development.
• NHS Ayrshire and ArrancoreStrategic or Co-development PartnerHealth board partner providing clinical advisors Dr. Kat Bjornsson (Public Health Lead) who ensures solutions are grounded in clinical excellence.
• NHS Greater Glasgow and ClydecoreStrategic or Co-development PartnerMajor NHS health board partner providing clinical expertise through advisors like Dr. Jen Sassarini (Consultant Gynaecologist) to ensure Seren meets real clinical needs.
• NHS Golden JubileecoreStrategic or Co-development PartnerNHS special health board supporting Lumino's digital health initiatives and improving outcomes for service users.
• Health Innovation EastcoreStrategic or Co-development PartnerHealth innovation network providing Dr. Sarah Robinson (Director of Delivery) as advisor, connecting Lumino with clinicians and researchers and supporting pilot programmes.
• Centre for Mood Disorders, University of ExetercoreStrategic or Co-development PartnerAcademic partner providing Professor Barney Dunn as advisor, bringing expertise in developing, evaluating, and implementing innovative psychological therapies.
• Judge Business School, University of CambridgecoreStrategic or Co-development PartnerEntrepreneurship Centre at Cambridge Judge provides academic guidance and credibility, supporting Lumino's strategic and business development.
• KoothcoreStrategic or Co-development PartnerDigital mental health pioneer founded by Elaine Bousfield, who provides advisory support on growth and strategy. Elaine describes Lumino as having 'capabilities for making a meaningful difference to the lives of millions of people.'
• University of East AngliacoreStrategic or Co-development PartnerAcademic partner providing Dr. Hannah Crook (Associate Professor in Clinical Psychology) who plays a key role in developing Lumino's evidence-based interventions.
• Bristol MindminorStrategic or Co-development PartnerMental health charity where co-founder Mo Morgan serves as trustee, connecting Lumino with lived experience and community perspectives.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Wysa: AI-driven conversational mental health platform providing CBT-informed self-help with clinical escalation pathways, used by health systems and employers globally. Comparable in CBT-grounded, scalable mental health delivery to NHS populations and employer wellness programmes.
• Sleepio: Digital therapeutic for insomnia using CBT, with NHS and employer distribution in the UK. Comparable as a clinically validated, CBT-based DTx distributed through NHS pathways and employer wellness programmes alongside Lumino's Seren.

Broad incumbents

• Babylon Health: UK-founded digital health company offering AI-powered triage, telehealth, and chronic condition management, with NHS contracts historically. Broad incumbent in the UK digital health ecosystem with overlapping NHS distribution, though operating across a much wider clinical scope.
• SilverCloud Health: Pioneer in internet-delivered CBT for depression, anxiety, and other mental health conditions, now part of Amwell. A broad incumbent offering overlapping CBT-based digital mental health programmes distributed through health systems, comparable in clinical-grade delivery and NHS-style deployment.
• Headspace Health: Major consumer and enterprise mental health platform combining meditation, mindfulness, and therapy services via employer and health plan partnerships. Broad incumbent in the same employer wellness and digital mental health category, though more consumer/generalist.

Direct peers

• Kooth: Listed UK digital mental health platform providing anonymous counselling and therapeutic support to young people and adults. Directly comparable in UK digital mental health distribution, NHS commissioning channels, and condition-specific programmes; Kooth's founder also formally endorses Lumino.
• Peppy: UK digital health platform delivering condition-specific support (notably menopause, fertility, and men's health) via employer benefits and B2B channels. Closely aligned with Lumino's Seren product in menopause, employer GTM motion, and subscription-based B2B model.
• Maven Clinic: US-based virtual care platform focused on women's and family health, including menopause support, distributed via employers and health plans. Comparable in condition-specific women's health focus, employer benefit GTM, and digital-first clinical delivery.
• Big Health: US/UK digital therapeutics company offering FDA-cleared, CBT-based programmes for insomnia and anxiety, distributed via employers, health systems, and payers. Highly comparable as a condition-specific, clinically validated, CBT-based DTx with enterprise sales motion.

Regional players

• Elvie: UK-based women's health technology company developing connected health devices and digital services across maternity and pelvic health. Comparable as a UK-rooted women's health brand applying digital technology to specific female health conditions, though more consumer hardware than DTx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hellolumino
• Xx.com/hello_lumino

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumino